The Swiss Zur Rose Group focuses on growth and expansion. However, Zur Rose’s most important major shareholder, Corisol, has now withdrawn and has placed its shares on the stock market. The Frey family of entrepreneurs, who own Corisol, acquired 22 percent of Zur Rose’s shares for 40 million Swiss francs at the time and wanted to support the growth strategy of Walter Oberhänsli, CEO of Zur Rose. Following the Saudi royal family’s entry and the IPO, the shares fell to 14.5 percent. A capital increase at the time of the takeover by Medpex also further diluted the shareholding, which the Frey family allegedly did not know. According to media reports, this led to disagreements due to alleged mishaps and differences of opinion between Cortisol and Zur Rose. A stock slide from 130 euros at the beginning of the IPO to 80 euros led to further bad developments between the two companies. The major shareholder of Zur Rose then probably took the consequences and withdrew. The block of shares, according to a report referring to traders, was sold. 900,000 shares, corresponding to a 10.8 percent share, were consequently sold for 103 million Swiss francs and went on the stock market as an offer last week. 115 francs per share were sold as a package. The exact stock market announcement will follow. It is still uncertain whether a new major shareholder will join the company, in addition to the existing ones such as those already mentioned and the financial investors Portsea, Wellington and T. Rowe Price, but also funds of the asset managers Patrick Schmitz-Morkrtamer and Patrick Bierbaum. Perhaps there will also be many different smaller investors who can benefit from the e-prescription boom Zur Roses as an online mail-order company
